- Gastrointestinal Cancer
  - Gastroesophageal cancer
    - Gastric and gastroesophageal junction adenocarcinoma
      - **10211:** A Phase 2 Single-Arm Study of M6620 in Combination with Irinotecan in Patients with Progressive TP53 Mutant Gastric and Gastro-Esophageal Junction Cancer
    - Esophageal and gastroesophageal junction adenocarcinoma
      - **10389:** A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) with Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer
    - Gastroesophageal or Colorectal Cancer
      - **10358:** Phase 1/1B Study of DS8201a in Combination with ATR Inhibition (AZD6738) in Advanced Solid Tumors with HER2 Expression (DASH Trial) (Dose escalation: advanced solid tumors; Dose expansion: Gastroesophageal or Colorectal Cancer)
      - **10406:** Phase 1/1b Trial of ATR Inhibitor BAY 1895344 in Combination with FOLFIRI in GI Malignancies with a Focus on Metastatic Colorectal and Gastric/Gastroesophageal Cancers
  - Colorectal cancer
    - Metastatic colorectal cancer
      - ***▼10579:** Phase I Trial of ZEN-3694 in Combination with Capecitabine in Patients with Solid Tumors New
    - Adenocarcinoma of the rectum
      - **10410:** A Phase 1 Study of IPdR in Combination with Capecitabine and Radiotherapy in Rectal Cancer
  - Liver and hepatobiliary cancer
    - Cholangiocarcinoma
      - **10222:** Phase II Study of Olaparib and AZD6738 in Isocitrate Dehydrogenase (IDH)-Mutant Solid Tumors (2 cohorts: cholangiocarcinoma and other solid tumors)
      - **10129:** A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors (3 cohorts: glioma, cholangiocarcinoma, and other solid tumors)
      - 10476: A Randomized Phase 2 Study of Combination Atezolizumab and CDX-1127 (Varlilumab) with or Without Addition of Cobimetinib in Previously Treated Unresectable Biliary Tract Cancers
    - Cholangiocarcinoma/ gallbladder carcinoma
      - **10276:** A Phase I/II Study of M3814 and Avelumab in Combination with Hypofractionated Radiation in Patients with Advanced/ Metastatic Solid Tumors and Hepatobiliary Malignancies (Phase 1: Limited; advanced/metastatic solid tumors; Phase 2: ETCTN-wide; advanced/metastatic hepatobiliary tumors)
  - Pancreatic cancer
    - Mesothelin-positive advanced pancreatic adenocarcinoma
      - **10208:** A Phase I/II study of Anetumab Ravtansine in Combination with Either Anti-PD-1 Antibody, or Anti-CTLA4 and Anti-PD -1 Antibodies or Anti-PD-1 Antibody and Gemcitabine in Mesothelin-Positive Advanced Pancreatic Adenocarcinoma
    - Pancreatic ductal adenocarcinoma
      - **10403:** Phase 1 Trial of Gemcitabine Combined with the BAY1895344 ATR Inhibitor with Expansion Cohorts in Advanced Pancreatic and Ovarian Cancer (Dose escalation: advanced solid tumor malignancies; Expansion ovarian and pancreatic cohorts)
      - **10402:** BAY1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)
      - **10366:** A Phase 1/2 Study of M3814 (Peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma
      - ***10522:** A Phase I Clinical Trial of CA-4948 in Combination with Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma
    - Unresectable Pancreatic Cancer
      - **10464:** A Phase 1 Study of Olaparib in Combination with Durvalumab (MEDI4736) and Concurrent Radiation Therapy Following First-Line Chemotherapy in Locally Advanced Unresectable Pancreatic Cancer
  - Neuroendocrine Tumors
    - Gastroenteropancreatic / Pancreatic Neuroendocrine Tumors
      - **10388:** A Phase I Trial of Triapine and Lutetium Lu 177 Dotatate in Combination for Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
      - **10450:** A Phase 1b Study of M3814 (Peposertib) in Combination with Lutetium 177 Dotatate in Well-Differentiated Somatostatin Receptor-Positive Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
      - ***10479:** A Phase I Dose Escalation-Expansion Trial of Sunitinib Malate Plus Lutetium Lu 177 Dotatate (Lutathera) in Somatostatin Receptor Positive Pancreatic Neuroendocrine Tumors

NOTE: * No ClinicalTrials.gov webpage is available at this time (typically for approved LOIs or protocols in review); ▼ Limited trial; not open ETCTN-wide; Version Date: November 10, 2022